References
- Mason P. Central mechanisms of pain modulation. Curr Opin Neurobiol 1999;9:436–41.
- Mense S. Neurobiological concepts of fibromyalgia — the possible role of descending spinal tracts. Scand J Rheumatol 2000;29 Suppl 113:24–9.
- Mossner R, Lesch KP. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun 1998;12:249–71.
- Boess FG, Martin IL. Molecular biology of 5-HT receptors. Neuropharmacology 1994;33:275— 317.
- Glennon RA. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem 2003;46:2795— 812.
- Wolf H. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scand J Rheumatol 2000;29 Suppl 113:37–45.
- Richardson BP, Engel G, Donatsch P, Stadler PA. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 1985; 316:126.
- Giordano J, Rogers LV. Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats. Eur J Pharmacol 1989;170:83–6.
- Giordano J, Dalco C, Sacks SM. Topical ondansetron attenuates nociceptive and inflammatory effects of intradermal capsaicin in humans. Eur J Pharmacol 1998;354:13–4.
- Saria A, Javorsky F, Humpel C, Gamse R. 5-HT3-receptor antagonists inhibit sensory neuropeptide release from the rat spinal cord. Neuroreport 1990;1:104–6.
- Saria A, Javorsky F, Humpel C, Gamse R. Endogenous 5-hydroxytryptamine modulates the release of tachykinins and calcitonin gene-related peptide from the rat spinal cord via 5-HT3 receptors. Ann N Y Acad Sci. 1991;632:464–5.
- Ambesh SP, Dubey PK, Sinha PK. Ondansetron pretreatment to alleviate pain on propofol injection: a randomized, controlled, double-blinded study. Anesth Analg 1999;89: 197–9.
- Ebersberger A, Anton F, Tolle TR, Zieglgansberger W. Mor-phine, 5-HT2 and 5-HT3 receptor antagonists reduce c-fos expres-sion in the trigeminal nuclear complex following noxious chemical stimulation of the rat nasal mucosa. Brain Res 1995;676:336–42.
- Ali Z, Wu U, Kozlov A, Barasi S. The role of 5-HT3 in nociceptive processing in the rat spinal cord: results from behavioural and electrophysiological studies. Neuroscience Letters 1996;208:203–7.
- Yonehara N. Influence of serotonin receptor antagonists on substance P and serotonin release evoked by tooth pulp stimulation with electro-acupuncture in the trigeminal nucleus caudalis of the rabbit. Neurosci Res 2001;40:45— 51.
- Parada CA, Tambeli CH, Cunha FQ, Ferreira SH. The major role of peripheral release of histamine and 5-hydroxytryptamine in formalin-induced nociception. Neuroscience 2001;102:937–44.
- Voog 0, Alstergren P, Leibur E, Kallikorm R, Kopp S. Immediate effects of the serotonin antagonist granisetron on temporomandibular joint pain in patients with systemic inflammatory disorders. Life Sci 2000;68:591 —602.
- Stratz T, Miller W. The use of 5-HT3 receptor antagonists in various rheumatic diseases —a clue to the mechanism of action of these agents in fibromyalgia? Scand J Rheumatol 2000;29 Suppl 113:66–71.
- Niissalo S, Hukkanen M, Imai S, Tornwall J, Konttinen YT. Neuropeptides in experimental and degenerative arthritis. Ann N Y Acad Sci 2002;966:384 — 99.
- Williams RO. Therapeutic effect of vasoactive intestinal peptide in collagen-induced arthritis. Arthritis Rheum 2002; 46:271— 3.
- Jorgensen C, Sany J. Modulation of the immune response by the neuroendocrine axis in rheumatoid arthritis. Clin Exp Rheumatol 1994;12:435 —41.
- Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter- and intraobserver variability of the total thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281–5.
- Matucci-Cerinic M, Giacomelli R, Pignone A, Cagnoni ML, Generini S, Casale R, et al. Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (sclero-derma). Ann Rheum Dis 2001;60:487 — 94.
- Klimiuk PS, Grennan A, Weinkove C, Jayson MI. Platelet serotonin in systemic sclerosis. Ann Rheum Dis 1989;48:586–9.
- Kissin EY, Korn JH. Fibrosis in scleroderma. Rheum Dis Clin North Am 2003;29:351 —69.
- Kasho M, Sakai M, Sasahara T, Anami Y, Matsumura T, Takemura T, et al. Serotonin enhances the production of type IV collagen by human mesangial cells. Kidney Int 1998; 54:1083–92.
- Ortonne JP, Torzuoli C, Dujardin P, Fraitag B. Ketanserin in the treatment of systemic sclerosis: a double-blind controlled trial. Br J Dermatol 1989;120:261 — 6.